TITLE

CD133 and BMI1 expressions and its prognostic role in primary glioblastoma

AUTHOR(S)
SIBIN, M. K.; LAVANYA, C. H.; BHAT, DHANANJAYA I.; RAO, NARASINGA; GEETHASHREE, N.; VIBHUTI, W.; CHETAN, G. K.
PUB. DATE
December 2015
SOURCE
Journal of Genetics;Dec2015, Vol. 94 Issue 4, p689
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Glioblastoma is the most common malignant brain tumour, generated by bulk of malignant cancer stem cells, which express various stem cell factors like CD133, BMI1 and nestin. There are several studies which show the importance of CD133 in cancer, but the function and interaction with other major oncogenes and tumour suppressor genes is still not understood. This study aimed to analyse the expression of CD133 mRNA and its correlations with BMI1 protein expression and TP53 mutations in newly diagnosed glioblastoma patients and its role in prognosis. Overexpression of CD133 mRNA and BMI1 protein was found in 47.6 and 76.2% patients respectively and TP53 mutations was seen in 57.1% of patients in our study. There was no correlation among TP53 mutations and expressions of CD133 and BMI1. We found that high level of BMI1 expression was favourable for the patient survival (P = 0.0075) and high CD133 mRNA expression was unfavourable for the patient survival (P = 0.0226). CD133 mRNA and BMI1 protein expression could independently predict the glioblastoma patient survival in multivariate analysis. In conclusion, the overexpression of these stem cell markers is a common event in glioblastoma progression and could be used as potential prognostic markers.
ACCESSION #
112050811

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics